Cromakalim does not act as a calcium antagonist in isolated human mesenteric artery cells.
The effects of cromakalim and its active enantiomer BRL 38226 on voltage-gated Ca2+ channels in smooth muscle cells isolated from human mesenteric arteries were studied using the whole cell patch-clamp technique. Neither of these drugs affected the Ca2+ channel current in these cells. These results suggest that the efficacy of cromakalim in lowering blood pressure in human beings does not involve a Ca2+ channel antagonistic effect.